HALO News Alert Halozyme Therapeutics (HALO) 9.34 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Halozyme Therapeutics (HALO) 9.34 $HALO

Halozyme's PEGPH20 tagged an Orphan Drug in Europe
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 9:31AM CST

HALO: 9.34 (+0.31)

Halozyme Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer
PR Newswire - Fri Dec 19, 7:30AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA), has designated PEGylated recombinant human hyaluronidase (PEGPH20) an orphan medicinal product for the treatment of pancreatic cancer. Halozyme is currently conducting a Phase 2 study on the treatment of metastatic pancreatic cancer with PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE®). In October 2014, the Company disclosed that the U.S. Food and Drug Administration also granted Orphan Drug designation for PEGPH20 for the treatment of pancreatic cancer.
HALO: 9.34 (+0.31)

Halozyme Up on Collaboration and Licensing Deal with J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 5:48PM CST
Shares of Halozyme (HALO) jumped after announcing a worldwide collaboration and license agreement with Johnson & Johnson (JNJ).
JNJ: 104.59 (+0.31), HALO: 9.34 (+0.31), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15)

Deal Street: Analyst Coverage on Visteon, Halozyme, Coca-Cola, Groupon and Barrick Gold
PR Newswire - Thu Dec 18, 8:30AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations including Visteon (NYSE: VC), Halozyme (NASDAQ: HALO), Coca-Cola (NYSE: KO), Groupon (NASDAQ: GRPN), and Barrick Gold (NYSE: ABX). Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
KO: 42.94 (-0.03), VC: 106.06 (+0.52), HALO: 9.34 (+0.31), ABX: 10.31 (+0.14), GRPN: 7.89 (-0.14)

Janssen Biotech licenses Halozyme's Enhanze technology
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:30AM CST

JNJ: 104.59 (+0.31), HALO: 9.34 (+0.31)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:13AM CST

CERS: 6.49 (+0.29), FRO: 2.43 (-0.01), KNDI: 12.90 (+0.99), GFI: 4.37 (+0.13), CLF: 6.06 (-0.09), NVGN: 2.40 (-0.09), ASPX: 49.93 (-0.10), DRIV: 24.49 (+0.09), SID: 2.24 (-0.08), HALO: 9.34 (+0.31), VOLC: 17.95 (+0.02), POZN: 7.86 (+0.07), ICLD: 3.00 (-0.02), TASR: 26.86 (+0.84), DGLY: 15.62 (+0.82), SBGL: 7.13 (+0.20)

Halozyme Therapeutics Enters A Global Collaboration With Janssen To Develop And Commercialize Subcutaneous Products Using ENHANZE(TM) Technology
PR Newswire - Wed Dec 17, 8:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Janssen Biotech, Inc. (Janssen) for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme's ENHANZE(TM) technology. ENHANZE is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily modifies hyaluronan, a component of the extracellular matrix, to aid in the dispersion and absorption of other injected therapeutic drugs.
HALO: 9.34 (+0.31)

United States Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry Analytics 2014-2021 - Market to reach $39.5 billion by 2021
M2 - Mon Dec 15, 8:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/s847lc/vaccines_skin) has announced the addition of Plunkett Research Ltd's new report "Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.) to reach $39.5 billion by 2021 Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - Anika Therapeutics Inc - CSL Behring LLC - Emergent BioSolutions Inc - Halozyme Therapeutics Inc - LifeCell Corporation - Lifecore Biomedical Inc - MiMedx Group Inc - Organogenesis Inc - RTI Biologics Inc - Zoetis Inc For more information visit http://www.researchandmarkets.com/research/s8...cines_skin Source: Plunkett Research Ltd
ZTS: 43.84 (+0.87), RTIX: 5.20 (unch), HALO: 9.34 (+0.31), EBS: 27.64 (+1.28), ANIK: 38.26 (+0.73), MDXG: 11.17 (+0.17)

Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Fri Dec 12, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
BLUE: 88.76 (+3.23), BIIB: 340.89 (+5.13), ACAD: 30.95 (+0.78), NBIX: 21.33 (+0.09), HALO: 9.34 (+0.31)

Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting
PR Newswire - Fri Dec 12, 7:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) today. The first of the presentations includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of immune-based cancer therapy such as monoclonal antibodies (mAbs). The second presentation includes additional supportive preclinical information on the utility of hyaluronan (HA) as a potential biomarker for cancer treatments. PEGPH20 is an investigational PEGylated form of rHuPH20 under development by Halozyme. PEGPH20 degrades the hyaluronan coating that may provide a supportive environment in many solid tumors.
HALO: 9.34 (+0.31)

Can Pfizer’s Cholesterol Drug Catch Up To The Competition?
Leo Sun, The Motley Fool - Motley Fool - Thu Dec 11, 6:28AM CST
Pfizer 's revenue has dramatically declined since 2011, the year Lipitor went off patent in the U.S. The blockbuster cholesterol drug, which already lost exclusivity in several markets at the time, still generated sales of $9.6 billion that year,...
HALO: 9.34 (+0.31), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07)

Halozyme Therapeutics - Buy The Drug Delivery Platform And Get A Cancer Drug For Free
Small Pharma Analyst - at Seeking Alpha - Tue Dec 09, 10:56AM CST

HALO: 9.34 (+0.31)

Halozyme Therapeutics To Present At The 25th Annual Oppenheimer Healthcare Conference
PR Newswire - Wed Dec 03, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York on Wednesday, December 10, 2014 at 1:00 p.m. ET/10:00 a.m. PT. David Ramsay, Vice President and Chief Financial Officer, will provide a corporate overview.
HALO: 9.34 (+0.31)

Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
PR Newswire - Tue Nov 25, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 1:00 p.m. EDT/10:00 a.m. PDT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 9.34 (+0.31)

Halozyme Therapeutics Earnings Review: 14 Days after Announcement Shares Down 8.6% (HALO)
Comtex SmarTrend(R) - Mon Nov 24, 9:18AM CST
When Halozyme Therapeutics (NASDAQ:HALO) reported earnings 14 days ago on November 10th, 2014, analysts, on average, expected the company to report a loss of $0.14 on sales of $16.5 million. Halozyme Therapeutics actually reported a loss of $0.16 per share on sales of $14.6 million, missing EPS estimates by $0.02 and missing revenue estimates by $1.9 million. Since the company's report, shares of Halozyme Therapeutics have fallen from $9.32 to $8.52, representing a loss of 8.6% in the past 14 days.
HALO: 9.34 (+0.31)

Halozyme Therapeutics Earnings Review: 7 Days after Announcement Shares Down 8.4% (HALO)
Comtex SmarTrend(R) - Mon Nov 17, 3:10PM CST
A week ago on November 10th, 2014 Halozyme Therapeutics (NASDAQ:HALO) reported earnings and analysts, on average, expected a loss of $0.14 on sales of $16.5 million. The company actually reported a loss of $0.16 per share on sales of $14.6 million, missing EPS estimates by $0.02 and missing revenue estimates by $1.9 million. Since the company's report, shares of Halozyme Therapeutics have fallen from $9.32 to $8.54, representing a loss of 8.4% in the past 7 days.
HALO: 9.34 (+0.31)

Halozyme Therapeutics (HALO) Stock Is Slipping Today on Weak Third Quarter Earnings
at The Street - Tue Nov 11, 10:42AM CST
Halozyme Therapeutics (HALO) stock is down after the company reported lower than expected third quarter earnings late Monday.
HALO: 9.34 (+0.31)

Halozyme net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 7:55AM CST

HALO: 9.34 (+0.31)

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:33PM CST

HALO: 9.34 (+0.31)

Halozyme Therapeutics meets 3Q profit forecasts
Automated Insights - Mon Nov 10, 5:51PM CST
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $20.3 million in its third quarter.
HALO: 9.34 (+0.31)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 209

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 149

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 191

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 151

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Scatec Completes Initial Phase of Solar Power Plant Sale

Updated Category News Views 114

Scatec ASA, a heavyweight in the renewable energy arena, concluded the first phase of selling parts of its holdings in the Kalkbult, Linde, and Dreunberg solar power plants back in 2024. This deal was inked with Greenstreet 1 Proprietary Limited—a subsidiary under the STANLIB Infrastructure Fund II umbrella. Transaction Breakdown: Financials and Implications The...

Continue Reading
Taiwan Semiconductor Excels with Strong AI Demand and Profits

Updated Category News Views 227

Taiwan Semiconductor's Remarkable Performance Taiwan Semiconductor Manufacturing Co (NYSE: TSM) has recently reported outstanding financial results for the third quarter, which surpassed expectations and reflected the growing global demand for advanced microchip technologies. Investors celebrated as TSM stock saw gains following these impressive numbers, showing...

Continue Reading
China Eases Mortgage Burdens as Economy Faces Challenges

Updated Category News Views 246

The People's Bank of China (PBOC) dropped a bombshell back in mid-2024, mandating commercial banks to slash interest rates on all existing housing loans. This move was their bid to ease the financial burden on households grappling with an economy that just wouldn’t budge. You see, this wasn’t just some casual tweak; it was a strategic lifeline thrown into the...

Continue Reading
Dimethylolpropionic Acid Market Forecast: Growth Driven by Eco-Friendly Solutions

Updated Category News Views 88

Overview of the Dimethylolpropionic Acid Market The global market for dimethylolpropionic acid (DMPA) is set for substantial growth, with projections indicating an increase of USD 230.2 million from 2024 to 2028, as highlighted in recent analyses. This growth translates to a compound annual growth rate (CAGR) of 7.05%. A key factor driving this expansion is the tightening...

Continue Reading
Bowen Acquisition Corp Faces NASDAQ Delisting Risk Amid Non-Compliance

Updated Category News Views 257

Bowen Acquisition Corp's Delisting Notification from NASDAQ Bowen Acquisition Corp (NASDAQ: BOWN) has recently faced the daunting challenge of a potential delisting from the Nasdaq Global Market. The announcement came as a response to a delisting determination letter received on a notable date which has since raised concerns among investors and stakeholders alike....

Continue Reading